Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Client
- BIOGEN, INC.
- Filing UUID
- d7ea23a2-53b3-42ea-919b-f49d78aaac36
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues related to tax reform.
Trade-related public policy around tariffs and intellectual property.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.